人工智能在前列腺癌PSMA PET/CT影像中的应用
该范围综述依据PRISMA指南系统检索PubMed、Embase和Cinahl,纳入26篇文献,总结人工智能在前列腺癌PSMA PET/CT中用于原发肿瘤、局部复发和转移灶检测、病灶分类、肿瘤定量及预测/预后等方面的研究。多项研究显示人工智能算法与人工判读表现相似,但获准临床使用的人工智能工具很少。主要局限包括缺乏外部验证和前瞻性设计。
要点
- 多项研究显示人工智能算法在PSMA PET/CT判读中与人工判读表现相似。
- 获准临床使用的人工智能工具很少。
- 主要局限为缺乏外部验证和前瞻性设计。
核心结论
- 人工智能在PSMA PET/CT前列腺癌影像中覆盖原发肿瘤、局部复发和转移灶检测、病灶分类、肿瘤定量及预测/预后等多个方面。
- 多项研究显示人工智能算法与人工判读表现相似,但获准临床使用的人工智能工具很少。
- 主要局限包括缺乏外部验证和前瞻性设计。
- 展示人工智能工具的临床影响和效用对其在医疗环境中被采用至关重要。
- 需要跨机构和设备的独立验证研究以确保稳健性,从而迈向可提供定量数据的临床有价值的人工智能工具。
研究设计与样本
- 本研究为范围综述,依据PRISMA指南在PubMed、Embase和Cinahl进行系统文献检索。
- 共纳入26篇文献进行综合。
主要发现
- 纳入研究聚焦人工智能在PSMA PET/CT中的不同方面,包括原发肿瘤、局部复发和转移灶检测、病灶分类、肿瘤定量及预测/预后。
- 多项研究显示人工智能算法与人工判读表现相似。
- 获准临床使用的人工智能工具很少。
局限性
- 主要局限包括缺乏外部验证和前瞻性设计。
- 需要跨机构和设备的独立验证研究以确保稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as an important imaging technique for prostate cancer. The use of PSMA PET/CT is rapidly increasing, while the number of nuclear medicine physicians and radiologists to interpret these scans is limited. Additionally, there is variability in interpretation among readers. Artificial intelligence techniques, including traditional machine learning and deep learning algorithms, are being used to address these challenges and provide additional insights from the images. The aim of this scoping review was to summarize the available research on the development and applications of AI in PSMA PET/CT for prostate cancer imaging. A systematic literature search was performed in PubMed, Embase and Cinahl according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 26 publications were included in the synthesis. The included studies focus on different aspects of artificial intelligence in PSMA PET/CT, including detection of primary tumor, local recurrence and metastatic lesions, lesion classification, tumor quantification and prediction/prognostication. Several studies show similar performances of artificial intelligence algorithms compared to human interpretation. Few artificial intelligence tools are approved for use in clinical practice. Major limitations include the lack of external validation and prospective design. Demonstrating the clinical impact and utility of artificial intelligence tools is crucial for their adoption in healthcare settings. To take the next step towards a clinically valuable artificial intelligence tool that provides quantitative data, independent validation studies are needed across institutions and equipment to ensure robustness.
引用
- Lindgren Belal S, Frantz S, Minarik D, et al. Applications of Artificial Intelligence in PSMA PET/CT for Prostate Cancer Imaging. Semin Nucl Med. 2023. PMID: 37357026. doi:10.1053/j.semnuclmed.2023.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。